Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6631-22-7

Post Buying Request

6631-22-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6631-22-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 6631-22-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,6,3 and 1 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 6631-22:
(6*6)+(5*6)+(4*3)+(3*1)+(2*2)+(1*2)=87
87 % 10 = 7
So 6631-22-7 is a valid CAS Registry Number.

6631-22-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name N,N'-(ethane-1,2-diyl)diisonicotinamide

1.2 Other means of identification

Product number -
Other names N-[2-(pyridine-4-carbonylamino)ethyl]pyridine-4-carboxamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6631-22-7 SDS

6631-22-7Downstream Products

6631-22-7Relevant articles and documents

Preparation and crystal structural study of a novel coordinated polymer [HgI2(4-bped)2] (bped = bis(4-pyridyl)ethylene diamine)

Liang, Yu,Zhao, Fukai,Wang, Qingli,Niu, Yunyin

, p. 763 - 766 (2011)

A novel coordinated polymer [HgI2(4-bped)2] was synthesized through the reaction of bis(4-pyridyl)ethylene diamine and HgI 2 in mixed MeOH-THF (5:2). The crystal structural analysis indicated that the complex crystallized in a monoclinic space group P21/c, a = 10.8392(12), b = 19.841(2), c = 8.8279(10), β = 95.452(2), V = 1889.9(4) A3, Z = 4. The complex possessed a novel three-dimensional supramolecular framework formed by hydrogen bonds among repeating [HgI 2(4-bped)]2 dimeric units.

Structural diversity and variable temperature magnetic properties in copper dimethylmalonate coordination polymers containing dipyridyl-type coligands

Kalman, Colton J.,Stone, Brandon S.,LaDuca, Robert L.

, p. 674 - 682 (2019)

Four copper dimethylmalonate (dmmal) phases containing long-spanning dipyridyl coligands have been prepared and structurally characterized by single-crystal X-ray diffraction. {[Cu2(dmmal)2(edin)(H2O)2]·3H2O}n (1, edin = N,N′-(ethane-1,2-diyl)diisonicotinamide) and {[Cu2(dmmal)2(bdin)(H2O)2]·2H2O}n (2, bdin = N,N′-(butane-1,4-diyl)diisonicotinamide) both show (6,3) herringbone layers constructed from the edin pillaring of [Cu(H2O)(dmmal)]n chain motifs, that feature embedded equatorial-equatorial bridged {Cu(OCO)}n chains. [Cu2(dmmal)2(bpmp)]n (3, bpmp = bis(4-pyridylmethyl)piperazine) shows a decorated (4,4) grid topology built from bpmp pillared [Cu2(dmmal)2]n ribbon motifs, that feature embedded {Cu2(OCO)4} paddlewheel dimeric units. [Cu2(dmmal)2(bpfp)]n (4, bpfp = bis(4-pyridylformyl)piperazine) shows a 5-connected non-interpenetrated 3D 4466 sqp topology, formed from the bpfp pillaring of rectangular equatorial-equatorial bridged [Cu2(dmmal)2]n layers. Variable temperature magnetic studies were carried out on 1, 2 and 4, indicating predominant ferromagnetic superexchange within their equatorial-equatorial {Cu(OCO)}n chain motifs.

Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; Their synthesis, binding kinetics and cytotoxicity

Brown, Sarah D.,Trotter, Katherine D.,Sutcliffe, Oliver B.,Plumb, Jane A.,Waddell, Bruce,Briggs, Naomi E. B.,Wheate, Nial J.

, p. 11330 - 11339 (2013/06/26)

Picoplatin is a sterically hindered mononuclear platinum drug undergoing clinical trials. The 2-methylpyridine ring provides steric hindrance to the drug, preventing attack from biological nucleophiles. BBR3464 is a trinuclear platinum drug which was recently in Phase II clinical trials, and is highly cytotoxic both in vitro and in vivo; it derives this activity through the flexible adducts it forms with DNA. In this work we sought to combine the properties of both drugs to synthesise a family of sterically hindered, dinuclear platinum complexes as potential anticancer agents. The bis-pyridyl-based ligands were synthesised through a peptide coupling reaction using diaminoalkanes of differing lengths (n = 2, 4 or 8) and 4-carboxypyridine or 2-methyl-4-carboxypyridine. The resultant dinuclear platinum complexes were synthesised by reacting two equivalents of transplatin or mono-aquated transplatin to each ligand, followed by purification by precipitation with acetone. The unprotected complexes react faster with 5′-guanosine monophosphate (drug to nucleotide ratio 1:2; t1/2 = 2 h), glutathione (1:10, t1/2 = 55 min) and human serum albumin (HSA) (1:1, t 1/2 = 24 h) compared to their hindered, protected equivalents (5′-guanosine monophosphate, t1/2 = 3.5 h; glutathione = 1.7 h; HSA, t1/2 = 110 h). The complexes were tested for in vitro cytotoxicity in the A2780 and A2780/cp70 ovarian cancer cell line. The unprotected platinum complexes were more cytotoxic than their protected derivatives, but none of the complexes were able to overcome resistance. The results provide important proof-of-concept for the development of a larger family of sterically hindered multinuclear-based platinum complexes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6631-22-7